Angiotensin-(1-7) attenuates neointimal formation after stent implantation in the rat

被引:82
作者
Langeveld, B
van Gilst, WH
Tio, RA
Zijlstra, F
Roks, AJM
机构
[1] Univ Groningen Hosp, Dept Clin Pharmacol, NL-9713 AV Groningen, Netherlands
[2] Univ Groningen Hosp, Dept Cardiol, NL-9713 AV Groningen, Netherlands
关键词
angioplasty; angiotensin; aorta; hyperplasia; rats; vasodilation;
D O I
10.1161/01.HYP.0000149382.83973.c2
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Angiotensin-(1 - 7) is an endogenous, biologically active peptide of the renin-angiotensin system with vasodilatory, antithrombotic, and antiproliferative properties. This study examined the effects of angiotensin-(1 - 7) infusion on neointimal formation after stent placement in the rat. Male Wistar rats underwent stent implantation in the abdominal aorta or sham surgery. Subsequently, an osmotic minipump was placed for angiotensin-(1 - 7) (24 mug/kg per hour) or saline administration. After 4 weeks, histomorphometric and histological analyses were performed, and the endothelial function was measured in isolated thoracic aortic rings. Stent implantation resulted in equal mean injury scores within the groups. The angiotensin-( 1 - 7) - treated group displayed a significant reduction in neointimal thickness (112 +/- 8 versus 141 +/- 11 mum; P < 0.05), neointimal area (0.51 +/- 0.05 versus 0.70 +/- 0.07 mm(2); P < 0.05), and percentage stenosis (10.4 +/- 1.0 versus 14.0 +/- 1.3%; P < 0.05) compared with the saline-treated group. Furthermore, angiotensin( 1 - 7) infusion attenuated the stenting-induced impairment in endothelium-dependent relaxation (42.6 +/- 3.0 versus 64.5 +/- 6.0% of phenylephrine maximal contraction; P < 0.001). In conclusion, angiotensin-( 1 - 7) treatment attenuates neointimal formation after stent implantation in the rat, combined with an improvement of endothelial function.
引用
收藏
页码:138 / 141
页数:4
相关论文
共 26 条
[1]  
BEUSEKOM HMM, 1996, CARDIOVASC PATHOL, V5, P69
[2]   Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide [J].
Brosnihan, KB ;
Li, P ;
Ferrario, CM .
HYPERTENSION, 1996, 27 (03) :523-528
[3]   Comparison of zofenopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure [J].
Buikema, H ;
Monnink, SHJ ;
Tio, RA ;
Crijns, HJGM ;
de Zeeuw, D ;
van Gilst, WH .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 130 (08) :1999-2007
[4]   EFFECTS OF CONVERTING-ENZYME INHIBITORS ON ANGIOTENSIN AND BRADYKININ PEPTIDES [J].
CAMPBELL, DJ ;
KLADIS, A ;
DUNCAN, AM .
HYPERTENSION, 1994, 23 (04) :439-449
[5]   A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9 [J].
Donoghue, M ;
Hsieh, F ;
Baronas, E ;
Godbout, K ;
Gosselin, M ;
Stagliano, N ;
Donovan, M ;
Woolf, B ;
Robison, K ;
Jeyaseelan, R ;
Breitbart, RE ;
Acton, S .
CIRCULATION RESEARCH, 2000, 87 (05) :E1-E9
[6]   Pathological analysis of local delivery of paclitaxel via a polymer-coated stent [J].
Farb, A ;
Heller, PF ;
Shroff, S ;
Cheng, L ;
Kolodgie, FD ;
Carter, AJ ;
Scott, DS ;
Froehlich, J ;
Virmani, R .
CIRCULATION, 2001, 104 (04) :473-479
[7]   Counterregulatory actions of angiotensin-(1-7) [J].
Ferrario, CM ;
Chappell, MC ;
Tallant, EA ;
Brosnihan, KB ;
Diz, DI .
HYPERTENSION, 1997, 30 (03) :535-541
[8]   Angiotensin-(1-7) inhibits vascular smooth muscle cell growth [J].
Freeman, EJ ;
Chisolm, GM ;
Ferrario, CM ;
Tallant, EA .
HYPERTENSION, 1996, 28 (01) :104-108
[9]   Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor [J].
Guba, M ;
von Breitenbuch, P ;
Steinbauer, M ;
Koehl, G ;
Flegel, S ;
Hornung, M ;
Bruns, CJ ;
Zuelke, C ;
Farkas, S ;
Anthuber, M ;
Jauch, KW ;
Geissler, EK .
NATURE MEDICINE, 2002, 8 (02) :128-135
[10]   Angiotensin-(1-7)-stimulated nitric oxide and superoxide release from endothelial cells [J].
Heitsch, H ;
Brovkovych, S ;
Malinski, T ;
Wiemer, G .
HYPERTENSION, 2001, 37 (01) :72-76